Drugs / 68Ga-NeoBOMB1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT02931929 | Nov 2016 → Apr 2019 | gastrointestinal stromal tumor | Medical University Innsbruck | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03724253 | Jul 2018 → Jun 2019 | breast cancer, colorectal cancer, non-small cell lung carcinoma, prostate cancer +1 | Advanced Accelerator Applications | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | [68Ga]-NeoBOMB1 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03724253 ↗ |
| Modality | Diagnostic / imaging agent | “intravenous application of a radiopharmaceutical for Positron Emission tomography (PET)” NCT02931929 ↗ |
| Route | Intravenous | “intravenous application of a radiopharmaceutical” NCT02931929 ↗ |